• 1
    Tabuchi N, De Haan J, Boonstra PW, Van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 82833.
  • 2
    Edmunds LH Jr. Blood–surface interactions during cardiopulmonary bypass. J Card Surg 1993; 8: 40410.
  • 3
    Speekenbrink RGH, Wildevuur CRH, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg 1996; 112: 52330.
  • 4
    Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW. Formation of C1, C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 4781.
  • 5
    Chung JH, Gikakis N, Rao K, Drak TA, Colman RW, Edmunds H Jr. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996; 93: 20148.
  • 6
    Philippou H, Davidson SJ, Mole MT, Pepper JR, Burman JF, Lane DA. Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass. Arterioscler Thromb Vasc Biol 1999; 19: 24854.
  • 7
    Tedgui A, Mallat Z. Smooth muscle cells. Another source of tissue factor-containing microparticles in atherothrombosis. Circ Res 2000; 87: 812.
  • 8
    Bloed LJ, Chen L, Koningsberg WH, Bach R. Serum stimulation of quiescent human fibroblasts induces the synthesis of tissue factor mRNA followed by the appearance of tissue factor antigen and procoaguant activity. J Cell Physiol 1989; 139: 41823.
  • 9
    Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 10045.
  • 10
    Soejima H, Ogawa H, Yasue H, Nishiyama K, Kaikita K, Misumi K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb Res 1999; 93: 1725.
  • 11
    Wad H, Nakase T, Nakaya R, Minamikawa K, Wakita Y, Kaneko T, Ohiwa M, Deguchi K, Shirakawa S. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 1994; 45: 2326.
  • 12
    Paborsky LR, Caras IW, Fisher KL, Gorman CM. Lipid association, but not the transmembrane domain, is reuired for tissue factor activity. J Biol Chem 1991; 266: 219116.
  • 13
    Philippou H, Adami A, Davidson SJ, Repper JR, Burman JF, Lane DA. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 2000; 84: 1248.
  • 14
    Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PGM, Ten Have K, Eijsman L, Hack CE, Sturk A. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 353441.
  • 15
    Nieuwland R, Berckmans RJ, McGregor S, Böing AN, Romijn FPHTM, Westendorp RGJ, Hack CE, Sturk A. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 9305.
  • 16
    Maquelin KN, Nieuwland R, Lentjes EG, Böing AN, Mochtar B, Eijsman L, Sturk A. Aprotinin administration in the pericardial cavity does not prevent platelet activation. J Thorac Cardiovasc Surg 2000; 120: 5527.
  • 17
    Dors DM, Nuijens JH, Huijbregts CCM, Hack CE. A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII. Thromb Haemost 1992; 67: 6448.
  • 18
    Joop K, Berckmans RJ, Nieuwland R, Berkhout JRF, Hack CE, Sturk A. Cellular origin and utilization of different pathways of coagulation by microparticles from patients with multiple organ dysfunction syndrome. Thromb Haemost 2001; 85: 81020.
  • 19
    Berckmans RJ, Nieuwland R, Böing AN, Romijn F, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 63946.
  • 20
    Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 259.
  • 21
    Giesen PLA, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 23115.
  • 22
    Siddiqui FA, Desai H, Amirkhosravi A, Amaya M, Francis JL. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 24753.
  • 23
    Van Dijk D, Keizer AM, Diephuis JC, Durand C, Vos LJ, Hijman R. Neurocognitive dysfunction after coronary artery bypass surgery: a systematic review. J Thorac Cardiovasc Surg 2000; 120: 6329.
  • 24
    Reis SE, Polak JF, Hirsch DR, Cohn LH, Creager MA, Donovan BC, Goldhaber SZ. Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. Am Heart J 1991; 122: 47882.
  • 25
    DeLaria GA, Hunter JA. Deep venous thrombosis. Implications after open heart surgery. Chest 1991; 99: 2848.
  • 26
    Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99: 2794800.
  • 27
    Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JWA, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 24427.
  • 28
    Johnell M, Elgue G, Thelin S, Larsson R, Siegbahn A. Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the corline heparin surface. Scand Cardiovasc J 2002; 36: 3517.